NewsRx

Search our medical news database

Myelodysplastic Syndrome

Dacogen clinical study interim data clarification released

Published in Blood Weekly, April 8th, 2004

SuperGen Inc. (SUPG) announced that the company has released the Kaplan-Meyer curves from the primary interim analysis that was performed on the first 45 events in the 170-patient phase III clinical study of Dacogen (decitabine) injection in myelodysplastic syndrome (MDS).

The company previously released an interim analysis of the Phase III clinical study and discussed its analysis of that data during its February 13th, 2004, conference call.

The interim analysis of the data previously released by the company and relating to the first 45 events revealed that those receiving Dacogen had an increased time to acute myelogenous leukemia (AML) or death...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook